Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Newbury Pharmaceuticals AB (FRA:P52) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Newbury Pharmaceuticals AB had a gross margin of 33.42% for the quarter that ended in Feb. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Newbury Pharmaceuticals AB Gross Margin % Related Terms
Newbury Pharmaceuticals AB Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:P52 vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Newbury Pharmaceuticals AB (FRA:P52) has a Gross Margin % of 33.42% as of Feb. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Newbury Pharmaceuticals AB and its competitors. This is 13% below median its historical median of 38.46. Over the past decade, Newbury Pharmaceuticals AB's Gross Margin % has ranged from 16.26 to 43.53. According to the industry distribution chart, Newbury Pharmaceuticals AB ranks #798 out of 939 companies in the Drug Manufacturers industry, placing it in the top 85%.
Is Newbury Pharmaceuticals AB's Gross Margin % too high?
Newbury Pharmaceuticals AB's current Gross Margin % of 33.42% is 13% below median its 10-year median of 38.46. Over the past 10 years, this metric has ranged from a low of 16.26 to a high of 43.53. The Drug Manufacturers industry median Gross Margin % is 48.54. Newbury Pharmaceuticals AB's value of 33.42% is 31.1% below this industry median. Based on the distribution chart, Newbury Pharmaceuticals AB ranks #798 out of 939 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Newbury Pharmaceuticals AB ranks #798 out of 939 companies for Gross Margin %. This places Newbury Pharmaceuticals AB in the lower half of its industry. The industry median Gross Margin % is 48.54. Newbury Pharmaceuticals AB's value of 33.42% is 31.1% below this benchmark. Historically, Newbury Pharmaceuticals AB's own Gross Margin % has ranged from 16.26 to 43.53 over the past decade. While the company's 10-year median is 38.46 vs. the industry median of 48.54, Newbury Pharmaceuticals AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Newbury Pharmaceuticals AB's current Gross Margin % of 33.42% is 31.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current Gross Margin % is 33.42%, which is 13% below median its own 10-year median of 38.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current Gross Margin % of 33.42%. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current Gross Margin % is 33.42%, which is 13% below median its 10-year median of 38.46 and 31.1% below the Drug Manufacturers industry median of 48.54. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current Gross Margin % is 33.42% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.
Key valuation signals for FRA:P52:
Gross Margin %: 33.42% (13% below median its 10-year median of 38.46)
GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
Industry Position: 31.1% below the Drug Manufacturers median (#798 of 939)
No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score
Get the complete analysis for FRA:P52
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:P52 has been successfully added to your 
